Story perspectives

Diagens Biotechnology Surges 97% Post-Hong Kong IPO Amid Fertility Focus

3/30/2026

Summary

Story summary

Hangzhou Diagens Biotechnology uses AI-powered chromosome testing to boost profits after its recent Hong Kong listing.
The company aims to address China's declining fertility rates as many young people delay marriage and parenthood and sometimes need in vitro fertilization (IVF).
Founder Song Ning highlighted the market's growth potential.
Diagens shares opened at HK$219 on the trading debut.
The price later stood at HK$195, reflecting a 97% increase from the HK$99 offer.

1 of 1

Story summary

Hangzhou Diagens Biotechnology uses AI-powered chromosome testing to boost profits after its recent Hong Kong listing.
The company aims to address China's declining fertility rates as many young people delay marriage and parenthood and sometimes need in vitro fertilization (IVF).
Founder Song Ning highlighted the market's growth potential.
Diagens shares opened at HK$219 on the trading debut.
The price later stood at HK$195, reflecting a 97% increase from the HK$99 offer.